Literature DB >> 16822758

Modelling cytomegalovirus replication patterns in the human host: factors important for pathogenesis.

Roland R Regoes1, E Frances Bowen, Alethea V Cope, Dehila Gor, Aycan F Hassan-Walker, H Grant Prentice, Margaret A Johnson, Paul Sweny, Andrew K Burroughs, Paul D Griffiths, Sebastian Bonhoeffer, Vincent C Emery.   

Abstract

Human cytomegalovirus can cause a diverse range of diseases in different immunocompromised hosts. The pathogenic mechanisms underlying these diseases have not been fully elucidated, though the maximal viral load during infection is strongly correlated with the disease. However, concentrating on single viral load measures during infection ignores valuable information contained during the entire replication history up to the onset of disease. We use a statistical model that allows all viral load data sampled during infection to be analysed, and have applied it to four immunocompromised groups exhibiting five distinct cytomegalovirus-related diseases. The results show that for all diseases, peaks in viral load contribute less to disease progression than phases of low virus load with equal amount of viral turnover. The model accurately predicted the time of disease onset for fever, gastrointestinal disease and pneumonitis but not for hepatitis and retinitis, implying that other factors may be involved in the pathology of these diseases.

Entities:  

Mesh:

Year:  2006        PMID: 16822758      PMCID: PMC1634765          DOI: 10.1098/rspb.2006.3506

Source DB:  PubMed          Journal:  Proc Biol Sci        ISSN: 0962-8452            Impact factor:   5.349


  43 in total

1.  Cytomegalovirus (CMV) DNA load in plasma for the diagnosis of CMV disease before engraftment in hematopoietic stem-cell transplant recipients.

Authors:  A P Limaye; M L Huang; W Leisenring; L Stensland; L Corey; M Boeckh
Journal:  J Infect Dis       Date:  2000-12-27       Impact factor: 5.226

2.  Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation.

Authors:  V C Emery; C A Sabin; A V Cope; D Gor; A F Hassan-Walker; P D Griffiths
Journal:  Lancet       Date:  2000-06-10       Impact factor: 79.321

3.  Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors.

Authors:  G M Gillespie; M R Wills; V Appay; C O'Callaghan; M Murphy; N Smith; P Sissons; S Rowland-Jones; J I Bell; P A Moss
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 4.  Recent advances in the therapy and prevention of CMV infections.

Authors:  W G Nichols; M Boeckh
Journal:  J Clin Virol       Date:  2000-02       Impact factor: 3.168

5.  Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes.

Authors:  E McLaughlin-Taylor; H Pande; S J Forman; B Tanamachi; C R Li; J A Zaia; P D Greenberg; S R Riddell
Journal:  J Med Virol       Date:  1994-05       Impact factor: 2.327

6.  Area under the viraemia curve versus absolute viral load: utility for predicting symptomatic cytomegalovirus infections in kidney transplant patients.

Authors:  P Schäfer; W Tenschert; L Cremaschi; M Schröter; B Zöllner; R Laufs
Journal:  J Med Virol       Date:  2001-09       Impact factor: 2.327

Review 7.  Investigation of CMV disease in immunocompromised patients.

Authors:  V C Emery
Journal:  J Clin Pathol       Date:  2001-02       Impact factor: 3.411

8.  Decreased macular leukocyte velocity in human immunodeficiency virus-infected individuals.

Authors:  M C Lim; W G Cumberland; S L Minassian; S S Ransome; M J Cornish; B G Terry; G N Holland
Journal:  Am J Ophthalmol       Date:  2001-11       Impact factor: 5.258

9.  Human cytomegalovirus open reading frame TRL11/IRL11 encodes an immunoglobulin G Fc-binding protein.

Authors:  B N Lilley; H L Ploegh; R S Tirabassi
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 10.  Cytopathology or immunopathology? The puzzle of cytomegalovirus pneumonitis revisited.

Authors:  S M Barry; M A Johnson; G Janossy
Journal:  Bone Marrow Transplant       Date:  2000-09       Impact factor: 5.483

View more
  6 in total

Review 1.  Cytomegalovirus: recent progress in understanding pathogenesis and control.

Authors:  V C Emery
Journal:  QJM       Date:  2011-12-22

Review 2.  Viral kinetic modeling: state of the art.

Authors:  Laetitia Canini; Alan S Perelson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-06-25       Impact factor: 2.745

3.  Human cytomegalovirus detection by real-time PCR and pp65-antigen test in hematopoietic stem cell transplant recipients: a challenge in low and middle-income countries.

Authors:  Giovanni Breda; Bernado Almeida; Suzana Carstensen; Carmem M Bonfim; Meri B Nogueira; Luine R Vidal; Sergio M Almeida; Sonia M Raboni
Journal:  Pathog Glob Health       Date:  2013-09       Impact factor: 2.894

4.  Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy.

Authors:  S F Atabani; C Smith; C Atkinson; R W Aldridge; M Rodriguez-Perálvarez; N Rolando; M Harber; G Jones; A O'Riordan; A K Burroughs; D Thorburn; J O'Beirne; R S B Milne; V C Emery; P D Griffiths
Journal:  Am J Transplant       Date:  2012-05-17       Impact factor: 8.086

5.  Effects of donor/recipient human leukocyte antigen mismatch on human cytomegalovirus replication following liver transplantation.

Authors:  R W Aldridge; F M Mattes; N Rolando; K Rolles; C Smith; G Shirling; C Atkinson; A K Burroughs; R S B Milne; V C Emery; P D Griffiths
Journal:  Transpl Infect Dis       Date:  2015-01-09       Impact factor: 2.228

6.  Correlation of Cytomegalovirus (CMV) Disease Severity and Mortality With CMV Viral Burden in CMV-Seropositive Donor and CMV-Seronegative Solid Organ Transplant Recipients.

Authors:  Jacqueline M McBride; Daniel Sheinson; Jenny Jiang; Nicholas Lewin-Koh; Barbara G Werner; Jennifer K L Chow; Xiaoning Wu; Jorge A Tavel; David R Snydman
Journal:  Open Forum Infect Dis       Date:  2019-01-14       Impact factor: 3.835

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.